Veru Inc. (VERU) Stock Price & Analysis
Veru Inc. (VERU) rose 3.33% to USD 3.1 as of June 10, 2026 at 00:59 UTC, according to Nexqual real-time market data.
VERU last closed at USD 3; the session ranged USD 2.98–3.42 on volume of 2,357,278 shares. Market capitalization is $49.76M, with a 52-week range of USD 2.05–7.4 (NCM). Source: Nexqual, June 10, 2026 at 00:59 UTC.
Key Statistics (as of June 10, 2026 at 00:59 UTC)
| Price | USD 3.1 |
|---|---|
| Change | ▲ 3.33% (up) |
| Previous Close | USD 3 |
| Open | USD 3.03 |
| Day Range | USD 2.98 – 3.42 |
| 52-Week Range | USD 2.05 – 7.4 |
| Volume | 2,357,278 shares |
| Market Cap | $49.76M |
| Exchange | NCM |
Technical Analysis (VERU)
Nexqual's technical model rates VERU "STRONG BUY" based on 6 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:59 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.34 (neutral) |
| vs SMA50 | Above (USD 2.39) |
| MACD | 0.23 (positive) |
Analyst Ratings (VERU)
Wall Street analysts rate VERU "Strong Buy" based on 2 analysts, with a mean price target of USD 24.5 (range USD 24–25), per Nexqual as of June 10, 2026 at 00:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 24.5 |
| High Target | USD 25 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (VERU)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.29 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.47 ▲ beat |
| 2025-09-30 | USD 0.09 vs est -0.39 ▲ beat |
| 2025-06-30 | USD -0.53 vs est -0.5 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financials & Fundamentals (VERU)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.74% |
| Debt / Equity | 8.15 |
| Current Ratio | 6.19 |
| Total Cash | $30.66M |
| Total Debt | $2.83M |
| Free Cash Flow | $-14.29M |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financial Health Score (VERU)
Nexqual rates Veru Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:59 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $31M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Critical — ROE -52%, ROA -46.4% |
Ownership (VERU)
| Insider Ownership | +9.78% |
|---|---|
| Institutional Ownership | +23.92% |
| Shares Outstanding | 16.05M |
| Float | 13.48M |
| Short % of Float | +3.90% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Leadership (VERU)
Veru Inc. is led by Mitchell S. Steiner F.A.C.S. (age 64), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 00:59 UTC.
| Chairman, President & CEO | Mitchell S. Steiner F.A.C.S. (age 64) |
|---|---|
| Vice Chairman & Chief Corporate Officer | Harry D. Fisch F.A.C.S. (age 66) |
| Chief Scientific Officer | K. Gary Barnette (age 57) |
| CFO & Chief Administrative Officer | Michele Greco (age 66) |
| Executive Director of Investor Relations & Corporate Communications | Samuel Fisch |
Major Backers & Investors (VERU)
Notable institutional backers of Veru Inc. include Alyeska Investment Group, L.p., Oppenheimer & Co Inc, GSA Capital Partners LLP, according to Nexqual as of June 10, 2026 at 00:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alyeska Investment Group, L.p. | 6.23% |
| Oppenheimer & Co Inc | 1.22% |
| GSA Capital Partners LLP | 1.18% |
| Summit Financial, LLC | 0.95% |
| Millennium Management | 0.94% |
| Fidelity | 0.94% |
| Ikarian Capital, LLC | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.22% |
| Geode Capital | 1.15% |
| BlackRock | 0.71% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
From Veru Inc.'s Latest SEC 10-K Filing (filed 2025-12-17)
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc. | USD 22.23 | ▼ 0.09% |
| FLNA | Filana Therapeutics, Inc. | USD 1.42 | ▲ 7.58% |
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| TTOO | T2 Biosystems, Inc. | USD 0 | ▲ 0% |
| GOVX | GeoVax Labs, Inc. | USD 1.28 | ▼ 22.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:59 UTC. This page is informational and not investment advice.